February 26, 2018 07:37 AM EST
R&D

Ob­sE­va high­lights a pos­i­tive da­ta point from its PhI­II study of new fer­til­i­ty drug, beats a path to reg­u­la­tors

John Carroll

Editor & Founder

Ob­sE­va $OB­SV re­port­ed that its late-stage tri­al of their lead ther­a­py aimed at pro­mot­ing preg­nan­cies among women with low fer­til­i­ty came through with a boost …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times